QIAGEN Clinical Insight bioinformatics platform

Wednesday, 27 May, 2015 | Supplied by: QIAGEN Pty Ltd

QIAGEN has announced the launch of the QIAGEN Clinical Insight (QCI) bioinformatics content and software platform for clinical testing labs to interpret and report on genomic variants identified in next-generation sequencing (NGS). The first two supported applications for the bioinformatics platform are in oncology, for somatic and hereditary cancer testing.

The platform is an evidence-based decision support solution that evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical trials. Using a powerful software platform, the secure QCI web application and QIAGEN’s private data centre, clinicians can rapidly classify variants, identify treatment options and perform geographical clinical trial matching.

The product supports both germline and somatic test indication, which is important to labs offering diverse test indications. It provides full platform- and assay-agnostic interpretation and reporting workflow support, which enables clinical testing labs to reduce time and cost associated with NGS-based testing. It also provides access to the Allele Frequency Community, a large repository of ancestral and ethnic diversity data.

Online: www.qiagen.com
Phone: 03 9840 9800
Related Products

Cayman Chemical SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit

Cayman Chemical's SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit is a competitive assay...

DMT Starter System tissue organ bath system for education

The sleek Starter System by DMT is a tissue organ bath that teaches students about the variation...

PCR Biosystems RiboShield RNase Inhibitor

PCR Biosystems' RiboShield RNase Inhibitor is now available as a standalone product. The...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd